NCT00972179View on ClinicalTrials.gov

Safety Study of Tezepelumab (AMG 157) in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

September 15, 2009

Primary Completion Date

January 9, 2011

Study Completion Date

January 9, 2011

Conditions

Healthy Volunteers

Interventions

DRUG

Placebo

Administered by subcutaneous or intravenous injection.

DRUG

Tezepelumab

Administered by subcutaneous or intravenous injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00972179 - Safety Study of Tezepelumab (AMG 157) in Healthy Adults | Biotech Hunter | Biotech Hunter